C
rohn's disease (CD) is a common debilitating immunemediated pan-enteric inflammatory bowel disease, estimated to present itself during childhood or adolescents in 20% to 25% of patients. 1 In comparison to adults, pediatric CD is generally considered as more aggressive and with a higher rate of complications, which usually necessitate more intensive pharmacological and/or surgical treatments. 2, 3 Perianal involvement in CD is a potentially significant source of morbidity with high prevalence rate estimated to occur in approximately 30% of patients with CD over the course of disease. [4] [5] [6] [7] It includes both nonpenetrating pathologies including skin tags and anal fissures and penetrating pathologies such as perianal abscesses and fistulas (defined as fistulizing perianal disease).
Adult studies have demonstrated that perianal disease is a predictor for developing more complicated CD, including a more rapid progression from inflammatory to stricturing or penetrating phenotype. 8, 9 Similar data in the pediatric population are still scarce, although accumulating in recent years, implying a higher risk of surgical interventions in this population. 10 Whether the natural history of nonfistulizing perianal disease differs from fistulizing perianal disease is not entirely clear in both adults and children.
The current European Crohn's and Colitis Organization and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ECCO/ESPGHAN) guidelines for treatment of pediatric CD state that the presence of severe perianal disease is a predictive factor for poor outcome, which justifies a more aggressive treatment approach. 11 The aim of this study was to determine, within a large pediatric cohort with long-term follow-up, whether perianal disease (fistulizing and nonfistulizing) is associated with more severe outcomes in pediatric CD, and to explore phenotypic features which are associated with this phenotype.
MATERIALS AND METHODS

Settings and Design
Data were extracted retrospectively from the medical record of 296 pediatric patients diagnosed with CD at the Schneider Children's Medical Center between 2001 and 2015 and were followed up for at least 1 year (up to December 2016). The data were retrieved retrospectively from computerized structured electronic charts which contain all medical encounters including surgical interventions, hospitalizations, medications, central laboratory reports, anthropometrics, and clinical evaluation in each visit of each discipline. Only patients who had continuous follow-up till the time of data collection were included. For patients who completed their pediatric follow-up and underwent a transition process to adult care, medical records were retrieved from the adult gastroenterology institutes at both Rabin and Sheba Medical Centers. Diagnosis of CD was based on the accepted clinical, endoscopic, and histologic criteria. 12 Disease-specific outcomes included time to first biological therapy, time to first flair, time to first hospitalization, and time to intestinal resection.
Description of Variables
Explicit demographic, clinical, laboratory, therapeutic, anthropometric, endoscopic, and radiologic data were recorded at diagnosis for each patient. Height, weight, and body mass index were adjusted to age and gender SD scores (Z-scores) using Centers for Disease Control and Prevention growth charts. Disease phenotype at diagnosis was categorized according to the Paris classification. 13 Disease activity was assessed using the short pediatric CD activity index (shPCDAI), abbreviated PCDAI, and the Harvey Bradshaw Index which were previously validated. 14, 15 The retrospective nature of the study prevented the accurate calculation of the PCDAI. Family history was defined as any first-degree relative with an established diagnosis of inflammatory bowel disease. Data collected throughout the follow-up period included clinical outcomes (medical and surgical interventions, hospitalizations, and disease's exacerbations). At the end of follow-up, the aforementioned indices were used to reassess phenotypic changes. After data collection, patients were designated to 1 of 3 groups: (1) no perianal disease, (2) nonfistulizing perianal disease (skin tags and fissures), and (3) fistulizing perianal disease (fistulae and abscesses). Diagnosis of perianal disease was established according to clinical symptoms and physical and radiological examinations, when available. Data on magnetic resonance imaging (MRI) of the pelvis were available for 29/40 (73%) of patients with fistulizing perianal disease and for 20/70 (29%) of patients with nonfistulizing perianal disease. Of the 26 patients who developed fistulizing perianal disease during follow-up, 18 (70%) had MRI data. Analysis of data pertaining to the 3 groups was performed at diagnosis and during followup, in particular, time to hospitalization, surgical intervention, flair, and initiation of biological treatment.
Data Analysis
Categorical variables were reported as frequency and percentage and compared using chi-square test or Fisher's exact test. Continuous variables were evaluated for normal distribution using histogram and Q-Q plots. Normally distributed continuous variables were described as mean and SD, whereas nonnormally distributed continuous variables were reported as median and interquartile range (IQR). Continuous variables were compared using analysis of variance, independent sample T test, and Kruskal-Wallis or Mann-Whitney tests, as appropriated. Length of follow-up was evaluated using a reverse censoring method. Cox regression was used to evaluate the crude and adjusted association between exposure and outcomes. Time to biological therapy, first flare, hospitalization, and intestinal resection during follow-up were described using Kaplan-Meier plots. All statistical tests were 2-tailed and P , 0.05 was considered as statistical significance. All statistical tests were performed using SPSS (IBM, version 23, Armonk, NY). The study was approved by the local institutional review boards at the Schneider/Rabin Medical Center and at the Sheba medical center.
RESULTS
Of the 296 patients with CD followed during this study, 110 (37%) had perianal involvement on physical examination: 70 (24%) with nonfistulizing perianal disease and 40 (13.5%) with fistulizing perianal disease. The clinical characteristics of these 3 groups (no perianal disease, nonfistulizing disease, and fistulizing perianal disease) are summarized in Table 1 . Of the entire cohort, 123 (41.5%) were female patients and the median age was 14.2 years (IQR, 12.0-16.0). Patients were followed for a median duration of 8.5 years (IQR 5.2-11.7 years).
When comparing any perianal findings with no perianal findings, perianal involvement was associated with female sex (52% versus 37%, respectively, P ¼ 0.01). Nonfistulizing disease was twice more common in female patients compared with fistulizing disease and no perianal involvement (61% versus 35% versus 37%, respectively, P ¼ 0.01).
Maintenance immunomodulatory treatment after induction treatment was significantly more common in patients with fistulizing perianal disease as compared with both the groups with no perianal involvement and that with nonfistulizing disease (75% versus 53% and 46%, respectively, P ¼ 0.01), whereas other therapeutic options such as 5-aminosalycilic acid, partial nutritional therapy, or no treatment were less common. Laboratory findings, severity indices on diagnosis, anthropometric measures (body mass index, weight, and height) as expressed as Z-scores, and disease distribution or behavior did not differ between the 3 study groups. The seropositivity of antisaccharomyces cerevisiae antibody and the presence of granulomas in intestinal biopsies also did not demonstrate a difference between study groups.
Kaplan-Meier survival curves of disease outcomes are represented in Figure 1A -D. Overall, 53.9% of patients received biological anti-tumor necrosis factor (TNFa) treatment, either infliximab or adalimumab. Patients with nonfistulizing perianal disease were 2 times more likely to receive biological treatment than patients with no perianal involvement (hazard ratio [HR] ¼ 2.1, 95% CI, 1.4-3.0), whereas those with fistulizing disease were 1.7 times more likely to receive biological treatment compared with patients with no perianal involvement (HR ¼ 1.7, CI, 95% 1.1-2.7). Time to initiation of biological treatment occurred significantly earlier in patients with both nonfistulizing and fistulizing disease when compared with those with no perianal disease (P ¼ 0.002), with a median time to treatment of 2.6 years (IQR 1.3-4.0) in nonfistulizing group and 2.4 years (IQR 0.8-4.0) in the fistulizing group as opposed to 8.5 years (IQR 6.5-11.1) in patients with no perianal disease (Fig. 1A) .
Sixty-three percent of patients experienced an exacerbation of their disease during follow-up. Median time to first disease flare was 2.5 years (IQR 0.8-4.2), 2.2 years (IQR 0.1-4.4 years), and 4.8 years (IQR 1.9-7.6 years), in patients with no perianal involvement, nonfistulizing, and fistulizing perianal disease, respectively (P ¼ 0.1) (Fig. 1B) .
After initial diagnosis, 162 patients (57%) of patients in the study were hospitalized at least once. The causes of hospitalizations included disease exacerbations (75%), perianal abscess (16%), intestinal resection (4%), and infections (5%). Patients with both nonfistulizing and fistulizing perianal disease were more likely to be hospitalized (HR ¼ 1.66, 95% CI, 1.2-2.4 and HR ¼ 1.34, 95% CI, 0.9-2.1, respectively) and were also hospitalized significantly earlier (P ¼ 0.027) than patients with no perianal involvement. Median time to first hospitalization was 3.1 years (IQR 2-4.2 years) in patients with nonfistulizing disease and 5.5 years (IQR 2.5-8.4 years) in patients with fistulizing disease as compared with a median time of 5.7 years (IQR 3.8-7.6 years) in patients with no perianal disease (Fig. 1C) . When analyzing only the hospitalizations because of disease exacerbations, there was no significant difference among the 3 study groups (P ¼ 0.30), suggesting that the higher risk for hospitalization in patients with perianal findings was primarily attributed to perianal rather than luminal disease activity. Over the course of the study, 76 patients (26%) underwent bowel resection. Median time to intestinal resection was 12.1 years (IQR 11.2-13.1), for the entire cohort and did not show any significant difference among the 3 study groups (P ¼ 0.23) (Fig. 1D) . Nine patients of 26 with perianal abscess (35%) had an abscess drainage procedure during follow-up (4 seton insertions, 15%), whereas none of the patients underwent fistulotomy. The rest of the patients with perianal abscesses were treated conservatively.
At the end of follow-up (median of 8.5 years, IQR 5.2-11.7 years), the rate of complicated disease (stricturing or internal fistulizing) was significantly increased in both the nonfistulizing (35 patients, 50%) and fistulizing (22 patients, 55%) groups compared with that of the no perianal involvement group (58 patients, 31%, P ¼ 0.007). Both stricturing disease (43 patients, 39% versus 44 patients, 24%, P ¼ 0.01) and penetrating disease (14 patients, 13% versus 14 patients, 7%, P ¼ 0.05) were more prevalent at the end of follow-up for patients with perianal findings.
Nonfistulizing Perianal Disease as a Risk Factor for the Development of Fistulizing Disease
During a follow-up period of 8.5 years (IQR 5.2-11.7), 26 patients (13 from the nonperianal involvement group [7%] and 13 from the nonfistulizing group [19%]) of 256 patients with CD without fistulizing perianal disease at diagnosis developed perianal fistulae (10%) at a median time of 3.5 years (IQR 1.9-6.3). The clinical characteristics of these patients are summarized in Table 2 . Having nonfistulizing perianal findings at diagnosis was associated with a substantial risk for the development of perianal fistulae during the course of disease (HR 3.4, 95% CI, 1.6-7.3, P ¼ 0.002). Subanalysis of the nonfistulizing group who underwent a pelvic MRI before the development of fistulizing perianal disease still yielded a significant difference between groups (25% versus 7%, P ¼ 0.02). Figure 2 describes the Kaplan-Meier survival curve for being free of perianal fistulizing disease according to the presence of nonfistulizing perianal findings at diagnosis. The mean time for developing fistulae was 13.9 years (standard error 0.3) for the group with no perianal findings at diagnosis and 10.2 years (standard error 0.7) for the group with nonfistulizing disease. Other variables at diagnosis such as sex, age, disease severity, and therapeutic regimens were not associated with the risk of developing perianal fistulae during the disease course, although these negative findings might be attributed to the small sample size of patients developing new fistulizing disease.
DISCUSSION
In this study, we evaluated phenotypic, clinical features and long-term disease-specific outcomes in a relatively large cohort of pediatric patients with CD according to the presence of perianal findings. As was demonstrated in adults, pediatric perianal disease was associated with worse clinical outcomes. These patients, regardless of the fistulizing nature of perianal findings, had a significantly higher risk for worse disease-specific outcomes including shorter time to biological therapy and hospitalization as well as a higher rate of complicated disease at the end of followup. Nonfistulizing perianal disease at diagnosis increased the risk for the development of fistulizing perianal disease during the disease course with a hazard ratio of 3.4. Interestingly, phenotypic features at diagnosis did not differ significantly between groups except for a predominance of female sex in patients with perianal findings.
Overall, only 4 pediatric studies were designed to compare patients with and without perianal disease. 4, [16] [17] [18] These studies reported minor differences in phenotypic features at diagnosis such as higher rates tissue granulomata, 17 younger age, and low body mass index at presentation. 16 None of the studies reported an association with any other specific features suggesting a more severe phenotype or luminal complications. Despite the large number of patients in our cohort, we could not confirm specific phenotypic features in patients with perianal disease except for female predominance which is in contrast to previous pediatric studies, which demonstrated an association with male sex. 16, 18 Intriguingly, the female preponderance was attributed, mainly, to the nonfistulizing group. Fistulizing perianal disease was associated with greater use of immunomodulators as was previously reported. 4 This study had the virtue of assessing long-term diseasespecific outcomes at a median follow-up of 8.5 years, using survival analyses. Similar to previous studies performed in adults, we have shown that perianal disease at diagnosis predicted a more complicated disease course including internal fistulizing and stenotic disease. 8, 10, [19] [20] [21] We could also demonstrate an increased risk for biological therapy and hospitalization in children with perianal findings, further implying a greater burden of disease in these patients. The earlier use of biological agents in patients with fistulizing perianal disease is expected as anti-TNFa treatment which has become a standard of care for perianal fistulae; however, this explanation does not apply for the nonfistulizing group thus this association may truly represent a greater disease severity in these patients as well. In children, 2 studies reported a higher rate of intestinal resection in patients with perianal disease, 16, 22 although the latter study was conducted before the introduction of biologial agents as an early treatment for this phenotype. It is possible that the lack of association between perianal findings at diagnosis and an increased risk for intestinal resection in our study is attributed to the earlier use of anti-TNFa agents as was demonstrated in the survival analysis, which is in concordance with the findings by Keljo et al, 4 thus altering the natural history of the disease. It can also be related to the relatively low rate of intestinal resection in our study, which may have hampered the power of prediction analyses.
The large number of patients enabled us to stratify patients with perianal findings into those with skin tags and/or fissures only compared with patients with fistulizing disease. The natural history of noninflamed skin tags is not well documented. In adults, a single study demonstrated an overall benign nature of anal fissures and skin tags with most lesions being stable at 10 years of follow-up. 23 Our study suggests that nonfistulizing perianal disease at diagnosis poses a significant risk for developing fistulizing disease during the course of disease. In this study, the occurrence of perianal fistulizing disease during the disease course was 3 times more common in patients with nonfistulizing perianal findings at diagnosis compared with patients with no perianal findings. This observation challenges the assumption that nonfistulizing perianal lesions have a benign nature, thus implying that patients with such lesions should be carefully monitored using frequent and meticulous physical examination of the perianal region and perhaps also an earlier radiologic evaluation. These patients may also benefit from a "top down" strategy with an earlier introduction of biologics.
The mechanism by which perianal disease confers a greater risk for a more severe course is not entirely understood. The etiology of perianal disease seems to be related to interaction between microbiological, immunological, and genetic factors. 24 Similar genetic factors which are associated with more severe or complicated disease such as NOD2/CARD15 and IRGM 25, 26 might also serve as predisposing factors for perianal disease. An association of perianal disease with a susceptibility locus on chromosome 5 is still debated with studies exhibiting contradictive results. [27] [28] [29] [30] This is one of only a few studies assessing phenotypic and disease-specific outcomes in children with perianal CD. Our results are strengthened by the relatively large number of patients and by the comprehensive survival analyses during a long-term follow-up period in the era of biological treatment. Nevertheless, this study has several limitations. First, despite being one of the largest studies evaluating perianal disease in children, its retrospective nature limited complete data collection, including PCDAI, calprotectin, and endoscopic severity indices. Some perianal findings might have been missed although the perianal examination is an integral and mandatory part of the physical examination in our center. Moreover, data on MRI of the pelvis were not available for the entire cohort, thus patients with nonfistulizing perianal findings might have had underlying fistulae that might have been missed during physical examination. This study was performed on a relatively homogenous population of Israeli children who may have distinct phenotypic features, which may differ from other populations.
In conclusion, pediatric patients with CD with both fistulizing and nonfistulizing perianal disease have worse disease outcomes during the course of disease including a higher rate of complications. In the era of standard early anti-TNFa treatment for perianal disease, this phenotype is still associated with a more detrimental course. Therefore, our findings support a more aggressive management approach in these patients. Nonfistulizing perianal disease may require routine and frequent assessment of the lesions and perhaps early radiologic evaluation.
